Compare STKS & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STKS | CING |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.3M | 74.9M |
| IPO Year | 2011 | N/A |
| Metric | STKS | CING |
|---|---|---|
| Price | $1.99 | $7.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $4.38 | ★ $31.33 |
| AVG Volume (30 Days) | 14.8K | ★ 313.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $673,344,000.00 | N/A |
| Revenue This Year | $23.94 | N/A |
| Revenue Next Year | $5.93 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 102.35 | N/A |
| 52 Week Low | $1.70 | $3.20 |
| 52 Week High | $5.19 | $7.92 |
| Indicator | STKS | CING |
|---|---|---|
| Relative Strength Index (RSI) | 42.25 | 67.38 |
| Support Level | $1.89 | $3.58 |
| Resistance Level | $2.65 | $7.92 |
| Average True Range (ATR) | 0.12 | 0.50 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 7.69 | 95.37 |
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.